Ptc Therapeutics (PTCT) | Stock Overview & Key Data
Ptc Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $50.75
High: $52.07
on June 20, 2025
52 Week Range
Low: $28.72
High: $58.38
on June 28, 2024
on March 17, 2025
All-Time High: $78.72 on April 6, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.6B
EPS
7.05
P/E Ratio (TTM)
6.44
Forward P/E
-12.33
P/B Ratio
-19.08
PEG Ratio
-12.33
Div. Yield
N/A
ROE
33.08%
Beta
0.543
Debt to Equity
-13.37
Financial Highlights
Profitability
Gross Margin
98.91%
Operating Margin
-19.49%
Profit Margin
35.65%
Returns and Earnings
Return on Assets (TTM)
23.81%
Return on Equity (TTM)
33.08%
EBITDA
$35.4M
Net Income (TTM)
$629.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$22.71
Quarterly Revenue Growth (YoY)
-4.20%
Quarterly Earnings Growth (YoY)
459.73%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ptc Therapeutics PTCT | 3.60B Mid-cap | 7.58% | 2.24% | 7.75% | -1.25% | 6.41% | 46.08% | -5.11% | 0.49% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| BridgeBio Pharma BBIO | 9.39B Mid-cap | -1.86% | 9.43% | 52.95% | 36.31% | 78.12% | 98.46% | 379.29% | 69.75% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
| Bio-Techne TECH | 7.92B Mid-cap | 0.48% | 7.42% | 15.73% | -16.82% | -24.45% | -25.30% | -36.23% | -14.64% |
Ownership & Short Interest
Insider Ownership
2.47%
Institutional Ownership
102.12%
Shares Short
6M
Short Ratio
4.94
Short % of Shares Outstanding
8.37%
Average 10-Day Volume
2M
Average 90-Day Volume
1M
Ptc Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ptc Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PTCT's 52-week high and low?
- In the last 52 weeks, Ptc Therapeutics reached a high of $58.38 (on March 17, 2025) and a low of $28.72 (on June 28, 2024).
- What is the market cap and P/E ratio for PTCT?
- Curious about Ptc Therapeutics's size and valuation? Its market capitalization stands at 3.60B. When it comes to valuation, the P/E ratio (trailing twelve months) is 6.44, and the forward P/E (looking ahead) is -12.33.
- Does PTCT pay dividends? If so, what's the yield?
- As for dividends, Ptc Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ptc Therapeutics's main competitors or similar companies to consider before investing?
When looking at Ptc Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% BridgeBio Pharma
BBIO9.39B Healthcare Biotechnology 98.46% 379.29% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% Bio-Techne
TECH7.92B Healthcare Biotechnology -25.30% -36.23% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ptc Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Ptc Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 33.08%, the Debt to Equity ratio from the most recent quarter is -13.37, and its Gross Profit Margin stands at 98.91%.
- What is the recent revenue and earnings growth for PTCT?
- Looking at Ptc Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -4.20%, and quarterly earnings saw a YoY growth of 459.73%.
- How much of PTCT stock is held by insiders and institutions?
- Wondering who owns Ptc Therapeutics stock? Company insiders (like executives and directors) hold about 2.47% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 102.12%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.